TRECATOR Drug Patent Profile

« Back to Dashboard

When do Trecator patents expire, and what generic alternatives are available?

Trecator is a drug marketed by Wyeth Pharms and is included in one NDA.

The generic ingredient in TRECATOR is ethionamide. There is one drug master file entry for this compound. Additional details are available on the ethionamide profile page.

Summary for TRECATOR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	88
Patent Applications:	2,014
Drug Prices:	Drug price information for TRECATOR
What excipients (inactive ingredients) are in TRECATOR?	TRECATOR excipients list
DailyMed Link:	TRECATOR at DailyMed

See drug prices for TRECATOR

US Patents and Regulatory Information for TRECATOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	TRECATOR	ethionamide	TABLET;ORAL	013026-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Trecator Market Dynamics, Patent Position, and Financial Trajectory

Last updated: September 24, 2026

Trecator is the former branded formulation of ethionamide, an oral antimycobacterial used in multidrug treatment of tuberculosis, particularly drug-resistant tuberculosis. Its commercial trajectory is defined by generic substitution, limited clinical use, weak pricing power, poor tolerability, and procurement-driven demand. Trecator does not have the profile of a growth pharmaceutical asset. Public sources do not report standalone Trecator revenue, and the brand’s economic value is materially lower than that of newer multidrug-resistant tuberculosis products such as Sirturo, Pretomanid, and Delamanid.

What is Trecator and how is it used?

Trecator contains ethionamide, a thioamide antibiotic that inhibits mycolic-acid synthesis in Mycobacterium tuberculosis. The product was marketed as 250 mg tablets.

The FDA labeling positions ethionamide as a component of combination therapy for active tuberculosis when first-line agents cannot be used because of resistance or intolerance. It is not intended to be used as monotherapy because treatment failure and resistance development are major risks (U.S. Food and Drug Administration [FDA], n.d.-a).

Attribute	Trecator
Active ingredient	Ethionamide
Drug class	Thioamide antimycobacterial
Dosage form	Oral tablet
Historical strength	250 mg
Primary use	Multidrug-resistant or otherwise difficult-to-treat tuberculosis
Typical role	Add-on or substitute agent
FDA pathway	Legacy NDA approval
Current commercial model	Generic and public-procurement driven
Biosimilar exposure	None
Principal commercial weakness	Limited use and poor tolerability

Ethionamide is associated with gastrointestinal toxicity, metallic taste, anorexia, weight loss, hepatotoxicity, neurotoxicity, and thyroid effects. These adverse effects reduce adherence and make the drug less attractive when alternative agents are available.

When does Trecator lose exclusivity?

Trecator’s commercial exclusivity has effectively expired. Ethionamide is an old small-molecule tuberculosis drug, and the market is no longer protected by meaningful new-molecule exclusivity.

The key commercial distinction is between the historic brand and the active ingredient:

• The original Trecator product is a legacy product rather than a protected growth asset.
• Ethionamide is available through generic channels in several markets.
• Any remaining patents would be expected to relate to specific formulations, manufacturing processes, or jurisdictions rather than the basic active ingredient.
• No biosimilar pathway applies because ethionamide is a conventional small molecule.
• Generic competition, procurement tenders, and treatment-guideline changes determine market access more than patent expiry.

The FDA Orange Book remains the principal U.S. source for listed patents and regulatory exclusivity associated with approved drug products. For a legacy ethionamide product, the relevant commercial question is whether an active, enforceable listing blocks generic substitution. Trecator has no known current exclusivity profile comparable with a recently approved branded drug (FDA, n.d.-b).

What is the Orange Book status of Trecator?

Trecator is associated with a historical FDA new-drug application for ethionamide tablets. Its Orange Book relevance is limited because the product is a mature therapy with generic alternatives and no meaningful period of market exclusivity.

A historical NDA listing does not establish current commercial availability. FDA records distinguish between approved, discontinued, and withdrawn products. A discontinued product may remain visible in regulatory databases without supporting active branded sales.

For market analysis, the important points are:

1. Trecator is not a current U.S. exclusivity story.
2. No Paragraph IV litigation campaign is publicly associated with the product at the scale seen for major branded medicines.
3. Generic ethionamide products can compete on price where approved and commercially supplied.
4. The principal barriers are manufacturing quality, supply continuity, procurement qualification, and clinical preference.

How many patents cover Trecator?

The basic ethionamide molecule is not a commercially meaningful patent moat. Any relevant patent protection would likely involve:

• Tablet formulation or coating.
• Manufacturing or purification methods.
• Solid-state or polymorph claims.
• Combination regimens.
• Regional regulatory exclusivity.
• Supplier-specific intellectual property.

These categories do not create a durable branded franchise unless they are linked to a clinically differentiated formulation. Trecator has not established a premium, differentiated delivery system comparable with long-acting injectable tuberculosis products or newer combination regimens.

What formulations are protected by Trecator patents?

The principal historical product was an immediate-release oral tablet. Publicly visible product information does not indicate a commercially dominant extended-release, injectable, inhaled, or implantable Trecator formulation.

Formulation protection therefore has limited financial significance. Even where formulation patents exist, they would not necessarily prevent competitors from marketing standard immediate-release ethionamide tablets.

What is the FDA regulatory status of Trecator?

Ethionamide has an established regulatory history in the United States, but its current market position is different from that of an actively promoted branded product. The FDA label identifies the drug’s use in difficult tuberculosis cases and describes dosing, contraindications, drug interactions, and adverse reactions (FDA, n.d.-a).

The regulatory environment has become more demanding because tuberculosis treatment guidelines increasingly prioritize regimens with better efficacy, shorter duration, and improved tolerability. The World Health Organization has placed greater emphasis on all-oral regimens that use newer agents, including bedaquiline and pretomanid, when clinically appropriate (World Health Organization [WHO], 2022).

Ethionamide remains relevant when resistance patterns, contraindications, availability, or programmatic conditions limit the use of preferred agents. Its regulatory standing is therefore defensive rather than expansionary.

What market dynamics affect Trecator demand?

Trecator demand is determined by the number of drug-resistant tuberculosis patients who require ethionamide and by national treatment guidelines. It is not driven by consumer prescribing, chronic primary care use, or a broad commercial sales force.

Global tuberculosis burden

Tuberculosis remains a major global infectious disease. Drug-resistant tuberculosis represents a smaller patient population than drug-susceptible tuberculosis but requires more complex and expensive treatment. That creates a medically necessary market for reserve agents, including ethionamide, even when individual-product demand is limited (WHO, 2023).

Guideline displacement

Ethionamide faces structural displacement from:

• Bedaquiline-based regimens.
• Pretomanid-containing regimens.
• Delamanid.
• Linezolid.
• Clofazimine.
• Fluoroquinolones where susceptibility is retained.

WHO recommendations increasingly favor shorter and more effective regimens. Ethionamide is generally used when preferred agents are unavailable, contraindicated, or ineffective.

Procurement concentration

Purchases are concentrated among national tuberculosis programs, international donors, and public-health procurement agencies. The Global Drug Facility and similar channels emphasize quality-assured products, low prices, reliable delivery, and access in high-burden countries (Stop TB Partnership, n.d.).

This procurement structure suppresses price and limits the value of brand recognition. A supplier that loses a tender can lose access to an entire national program.

What is the financial trajectory for Trecator?

No public company filings provide a reliable standalone revenue series for Trecator. The product is generally aggregated within broader anti-infective, generic, or legacy-product reporting. The financial trajectory can therefore be assessed through market structure rather than reported brand sales.

Financial factor	Direction for Trecator
Unit demand	Low and clinically selective
Pricing	Downward pressure from generic procurement
Gross margin	Likely lower than newer branded TB therapies
Marketing expense	Limited
Patent value	Minimal
Working-capital risk	Meaningful because of small volumes and tender timing
Supply-chain value	High relative to brand value
Revenue visibility	Low
Growth potential	Limited without a differentiated formulation or regimen

Trecator’s revenue opportunity is constrained by four factors. First, the eligible patient population is narrow. Second, the drug is often used as a substitute rather than a preferred backbone therapy. Third, public procurement negotiates aggressively. Fourth, adverse effects reduce persistence and repeat demand.

The product can still generate stable niche revenue for a qualified generic supplier because tuberculosis programs require backup agents. That revenue is more likely to be predictable at the portfolio level than at the individual-brand level.

Which companies are challenging Trecator?

The competitive field is not centered on a branded Trecator challenger. It consists of generic ethionamide manufacturers and alternative tuberculosis-drug suppliers.

Competition occurs through:

• Regulatory approval of generic ethionamide tablets.
• WHO prequalification or other quality-assurance pathways.
• National tender awards.
• Reliable active-pharmaceutical-ingredient sourcing.
• Ability to maintain supply during public-health emergencies.
• Pricing and payment terms.

The more important competitive threat comes from alternative regimens rather than direct ethionamide copies. Bedaquiline-based combinations and pretomanid-containing regimens can reduce ethionamide use when they are clinically appropriate and accessible.

What patent litigation and Paragraph IV risks affect Trecator?

No major current Paragraph IV litigation or settlement framework is associated with Trecator’s legacy commercial position in the public sources reviewed. The product’s principal legal risks are more likely to involve:

• Generic abbreviated new drug application strategy.
• Labeling and substitution disputes.
• Manufacturing and quality compliance.
• Supply contracts.
• Tender challenges.
• Product liability involving hepatotoxicity or drug interactions.

Because the molecule is old and the market is genericized, litigation is unlikely to create material shareholder value unless a supplier asserts a narrow formulation or process patent.

How strong is the Trecator patent estate?

Trecator has a weak commercial patent estate. Its value lies in regulatory history, manufacturing capability, and procurement access rather than exclusivity.

Patent-estate category	Assessment
Original molecule patent	Commercially expired or immaterial
Core composition protection	Weak
Formulation patents	Limited commercial relevance
Method-of-use patents	Unlikely to block broad generic use
Manufacturing patents	Potentially relevant but narrow
Regulatory exclusivity	No meaningful current value
Litigation leverage	Low
Geographic protection	Fragmented by jurisdiction

What generic entry risks exist?

Generic entry is already the central market condition rather than a future event. Additional suppliers can intensify price competition, but the market may not support many manufacturers because volume is limited and quality requirements are high.

The main risks to an incumbent supplier are:

• Loss of a national or international tender.
• Price reductions after a new supplier qualifies.
• Regulatory inspection findings.
• API shortages.
• Changes in WHO treatment guidance.
• Substitution by bedaquiline, pretomanid, or delamanid.
• Patient and physician reluctance caused by tolerability problems.

A generic launch would not necessarily create a large revenue pool. The more likely outcome is redistribution of a small, procurement-driven market.

How does Trecator compare with newer tuberculosis drugs?

Drug	Commercial position	Clinical role	Patent and pricing profile
Trecator/ethionamide	Legacy generic	Reserve or substitute agent	Weak exclusivity, low pricing
Sirturo/bedaquiline	Branded and generic transition	Core MDR-TB regimen component	Stronger historic patent value
Pretomanid	Newer branded or partnership-based product	Used in defined shorter regimens	More differentiated regimen value
Delamanid	Newer MDR-TB option	Alternative companion drug	Greater innovation value than ethionamide
Linezolid	Generic, broad anti-infective	Important MDR-TB component	Generic, but broader demand
Clofazimine	Generic	Companion drug	Limited patent value

Trecator is commercially inferior to newer products on differentiation, tolerability, and regimen importance. Its advantage is established manufacturing, low cost, and continued utility when newer agents cannot be used.

What is the outlook for Trecator?

The base-case outlook is stable but declining relevance. Ethionamide is likely to remain available in selected tuberculosis programs because resistance patterns and access constraints require fallback options. Its use should continue to migrate toward narrowly defined cases as shorter, better-tolerated regimens expand.

Revenue will likely remain low, fragmented, and tender-dependent. A material improvement would require one of three developments: a clinically superior formulation, inclusion in a preferred modern regimen, or a supply disruption affecting competing agents. None represents the normal commercial trajectory of the product.

Key Takeaways

• Trecator is the legacy branded form of ethionamide.
• Its original composition-of-matter exclusivity has no meaningful current commercial value.
• No biosimilar risk exists because ethionamide is a small molecule.
• Generic competition and public procurement define the market.
• FDA and Orange Book relevance is primarily historical and regulatory.
• No material current Paragraph IV or settlement-driven risk is associated with the product’s market position.
• Newer tuberculosis therapies are reducing ethionamide’s role.
• Standalone Trecator revenue is not publicly disclosed.
• Financial value is concentrated in supply reliability and procurement access, not brand pricing power.
• The likely trajectory is niche, low-growth, and gradually declining clinical relevance.

FAQs About Trecator Market Economics

Is Trecator still commercially available?

Availability varies by country, supplier, and procurement program. Historical FDA approval does not guarantee current branded U.S. distribution.

Is ethionamide still recommended for multidrug-resistant tuberculosis?

Yes, but its use is more selective than in earlier treatment eras. Current guidelines prioritize newer, better-tolerated all-oral regimens when they are available and clinically appropriate (WHO, 2022).

Does Trecator have biosimilar competition?

No. Biosimilars apply to biologic products. Ethionamide is a conventional small-molecule drug and competes through generic approval pathways.

Can a generic company obtain exclusivity for ethionamide?

A generic manufacturer could obtain limited regulatory, formulation, or process protection in specific circumstances, but the basic ethionamide molecule does not provide a strong exclusivity platform.

What is the largest commercial threat to Trecator?

The largest threat is therapeutic substitution by newer tuberculosis regimens, followed by tender-based price competition and declining use in national treatment guidelines.

References

1. Stop TB Partnership. (n.d.). Global Drug Facility: Products and procurement. https://www.stoptb.org/gdf
2. U.S. Food and Drug Administration. (n.d.-a). Trecator (ethionamide) prescribing information.
3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations.
4. World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4: Treatment - drug-resistant tuberculosis treatment. World Health Organization.
5. World Health Organization. (2023). Global tuberculosis report 2023. World Health Organization.